A5070923889- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Advanced Radiotherapy Techniques
- Lymphoma Diagnosis and Treatment
- Pluripotent Stem Cells Research
- Glioma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- CRISPR and Genetic Engineering
- Pancreatic function and diabetes
- Radiation Therapy and Dosimetry
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Multiple Myeloma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Anesthesia and Neurotoxicity Research
- Management of metastatic bone disease
- Advanced MRI Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Salivary Gland Tumors Diagnosis and Treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Oral health in cancer treatment
The University of Texas MD Anderson Cancer Center
2021-2025
Mayo Clinic
2017-2021
WinnMed
2020
Memorial Sloan Kettering Cancer Center
2019
Mayo Clinic in Arizona
2018-2019
University of Iowa
2012-2018
Engineering Arts (United States)
2018
Veterans Health Administration
2017
Iowa City VA Medical Center
2017
University of Iowa Hospitals and Clinics
2013-2014
Atezolizumab plus bevacizumab has become frontline therapy for unresectable HCC. The compatibility of atezolizumab/bevacizumab with liver-directed RT not been reported. Methods: HCC patients treated and between 1/2020–11/2021 were included. Toxicity outcomes retrospectively recorded. For ALCs, we matched the analysis to a previously cohort RT-treated who did receive atezolizumab/bevacizumab. Survival time-to-liver-failure analyzed using Kaplan–Meier. Results: Of 21 patients, median follow-up...
Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T therapy (CAR-T). Here, we examined patient and treatment factors associated outcomes patterns of failure after bRT CAR-T. We retrospectively reviewed adults diffuse large B-cell (DLBCL) who received axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel between 11/2017-4/2023. Clinical/treatment characteristics,...
Osteoradionecrosis of the jaw (ORNJ) is a debilitating complication that affects up to 15% head and neck cancer patients who undergo radiotherapy. The ASCO/ISOO/MASCC-endorsed ClinRad severity classification system was recently proposed (and recommended in latest ASCO guidelines) incorporate radiographic findings for determining ORNJ based on vertical extent bone necrosis. However, variability imaging modalities specialty-specific knowledge may contribute disparities diagnosing classifying...
Cervical cancer (CC) disproportionately affects minorities who have higher incidence and mortality rates. Standard of care for locally advanced CC involves a multimodality approach including brachytherapy (BT), which independently improves oncologic outcomes. Here, we examine the impact insurance status race on BT utilization with SEER database.In total, 7,266 patients stage I-IV diagnosed from 2007 to 2015 were included. utilization, overall survival (OS), disease-specific (DSS)...
Background Single‐institution studies have shown the oncologic benefit of ablative liver radiotherapy (A‐RT) for patients with unresectable intrahepatic cholangiocarcinoma (ICC). However, adoption A‐RT across United States and its associated outcomes are unknown. Methods We queried National Cancer Data Base nonsurgically managed ICC diagnosed between 2004 2018. Patients were labeled receipt biologically effective doses (BED 10 ) ≥ 80.5 Gy conventional RT (Conv‐RT) lower doses. Associations...
Introduction: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that radiotherapy (L-RT) for locally advanced ICC associated less frequent TRLF and longer overall survival (OS), role L-RT extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes M1 treated without L-RT. Methods: reviewed found have at initial diagnosis a single institution between 2010 2021 who...
As the prevalence of therapeutic approaches involving transplanted cells increases, so does need to noninvasively track determine their homing patterns. Of particular interest is fate embryonic stem cell-derived hematopoietic progenitor (HPCs) used restore bone marrow pool following sublethal myeloablative irradiation. The early patterns cell engraftment are not well understood at this time. Until now, longitudinal studies were hindered by necessity sacrifice several mice various time points...
Intensity-modulated proton therapy (IMPT) demonstrates superior dose distribution over volumetric-modulated arc (VMAT) for sparing organs-at-risk (OARs) in ipsilateral radiotherapy. To determine a clinical benefit, assessment of patient-reported outcomes (PRO) and physician-reported toxicities alongside dosimetric analysis is needed.Plans were analyzed differences. PROs compared patients undergoing curative-intent radiotherapy tonsil salivary gland cancers with VMAT or IMPT from 2015 to...
To evaluate patients with clinical (c)T4 prostate cancer (PCa), which represent both a heterogenous and understudied population, who often present locally advanced disease obstructive symptoms causing significant morbidity mortality. We analysed whether receiving definitive local therapy influenced symptomatic oncological outcomes.Retrospective analysis of 154 cT4 PCa treated at single institution in 1996-2020. Systemic or without treatment (surgery, radiotherapy [RT], both). Uni-...
The safety of induced pluripotent stem cells (iPSCs) in autologous recipients has been questioned after iPSCs, but not embryonic (ESCs), were reported to be rejected syngeneic mice. This important topic remained controversial because there a mechanistic explanation for this phenomenon. Here, we hypothesize that ESCs, readily differentiate into gamete-forming express meiotic antigens normally found immune-privileged gonads. Because peripheral blood T are tolerized these the thymus,...
Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) organs is rare, and real-world outcomes after combined modality therapy (CMT) with systemic (ST) radiotherapy (RT) are not well-characterized, particularly in contemporary era. We characterized a cohort of GI-DLBCL patients treated ST alone or CMT.
Definitive intent radiation therapy (RT) for early-stage mucosa-associated lymphoid tissue (MALT) lymphoma typically includes a dose of 24 to 30 Gy. While modest, these doses may have associated toxicity. For patients with indolent B-cell lymphoma, there is increasing support the use ultra-low-dose RT (ULDRT) using 4 Gy in 2 fractions as part response-adapted approach, high rates complete response been documented. This paradigm has prospectively evaluated management orbital and gastric...